Oral COVID-19 Treatment VV116 Shows Promise with Minimal Impact from Liver Impairment

A new oral antiviral, VV116 (too known as mindeudesivir), is demonstrating encouraging results in clinical trials for the treatment of COVID-19, particularly regarding its pharmacokinetics and safety in individuals with mild to moderate liver impairment. Developed as a deuterated version of remdesivir, VV116 aims to overcome the limitations of intravenous remdesivir administration, offering a more accessible treatment option.

What is VV116?

VV116 (Mindvy, JT001) is an orally administered antiviral drug designed to treat COVID-19. It is a chemically modified version of remdesivir, incorporating deuterium to enhance its bioavailability. Research published in The Lancet Infectious Diseases highlights its potent anti-SARS-CoV-2 activity.

Study Findings on Liver Impairment

A Phase 1 study investigated the effects of mild to moderate hepatic impairment on the pharmacokinetics and safety of VV116. The study, involving adults with varying degrees of liver function, revealed that hepatic impairment did not significantly alter the overall exposure to the drug. Specifically:

• Drug Exposure (AUC): Overall exposure was comparable between participants with mild or moderate liver impairment and healthy controls (GMRs of 94.10% and 97.72%, respectively).
• Time to Maximum Concentration (Tmax) & Half-Life (t1/2): Median Tmax and t1/2 remained similar across all groups.
• Maximum Concentration (Cmax): Cmax was slightly lower in those with liver impairment, but this difference was not considered clinically significant.

Safety Profile

VV116 demonstrated a favorable safety profile in the study. Treatment-emergent adverse events were reported in 12.5% of the mild impairment group, 37.5% of the moderate impairment group, and 12.5% of the control group. All adverse events were mild or moderate in severity, transient, and resolved without intervention. Importantly, no serious adverse events, deaths, or study discontinuations occurred. According to research published in PubMed, the increased incidence of adverse events in the moderate impairment group was not linked to VV116 exposure levels.

Implications for Treatment

The findings suggest that dose adjustments of VV116 are likely unnecessary for patients with mild or moderate hepatic impairment. This is a significant advantage, simplifying treatment protocols and expanding access to this potentially valuable antiviral medication.

Looking Ahead

VV116 represents a promising advancement in oral COVID-19 therapeutics. Further research, including larger-scale clinical trials, will continue to evaluate its efficacy and safety in diverse patient populations. The development of orally available antivirals like VV116 is crucial for managing COVID-19 and mitigating the impact of future outbreaks.